Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Tebentafusp is being developed as a first-of-its-kind immunotherapy drug that showed promise in clinical studies in helping the immune system fight off melanoma cancers of both the eye and skin.

medical technology and dna concept © CRUK Oxford

 Immunotherapy is a mainstay of cancer treatment, helping the body use its own immune response to attack tumours. Thus far immunotherapy drugs have been used successfully in only some cancer types, such as cutaneous melanoma and lung cancer. These drugs (including checkpoint inhibitors) are less effective in patients whose tumour has fewer immune cells (particularly T cells) and lower mutational burden. This is thought to make it harder for the immune system to ‘see’ and target the tumour.

Metastatic uveal melanoma is one such type of cancer for which this is thought to be a problem, making it one of the deadliest cancers. However, a publication based on a collaboration between the University of Oxford and Immunocore has found that an investigational agent, tebentafusp, designed as a first-in-class bispecific fusion protein, shows the potential to treat both metastatic cutaneous melanoma (mCM, a skin cancer) and metastatic uveal melanoma (mUM, an eye cancer).

The full article is available to read on the Cancer Research UK - Oxford Centre website